Ido Yofe

Principal Investigator | Metastasis Genomics Research Group | Sheba Medical Center, Israel.

[Ido Yofe @IdoYofe]

🚀 YOFE LAB LAUNCHES 🚀
As a #newPI at Sheba Medical Center I'm building a cutting-edge research lab, addressing a critical challenge – how to stop #Cancer #Metastasis before it spreads.

Looking for research assistants and students to join us!
Apply here: [email protected]

[Merav Cohen Lab @MCohenLab]

We are thrilled to share the newest publication from our lab! In this work, @RoiBalaban & @OriMoskowitz investigated the effect of #efferocytosis on #macrophage state and function in the #TME.

https://t.co/cYK5CblvHz

[Ido Yofe @IdoYofe]

Which c̶a̶n̶c̶e̶r̶ spatial ecotype do you study?

[Aaron Newman Lab @AaronNewmanLab]

6/ These SEs are fundamental, geographically organized units of TME biology – the parts list for the tumor microenvironment across cancer types – each with distinct cell-state assemblies.

[Prof. Dr. Ahmet Dirican @dr_dirican]

In patients with stage II/III HER2-positive or triple-negative breast cancer receiving neoadjuvant therapy (NAT):
ctDNA tells the real story:

* Post-NAT ctDNA+ → HR 8.9 (recurrence risk)
* Post-op ctDNA+ → HR 128 (!! recurrence risk)
* ctDNA− → 5y IDFS 94%

Not a response marker.
A recurrence biology marker.

pCR is a snapshot.
ctDNA is the future.

👉 We now need trials testing escalation strategies in ctDNA-positive patients —
and whether converting ctDNA to negative improves outcomes.

@OncoAlert @myESMO @ASCOPost @PTarantinoMD @Dr_Oncologista #breastcancer

https://t.co/FXjVHAXkOB

[Judith Agudo @JudithAgudo1]

Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!🤯
⁦thanks to ⁦@nyscf⁩ ⁦@parkerici⁩ for their support. Today at ⁦@Nature⁩ https://t.co/rMKnHEqQwb

[Roth_Lab @Roth_Lab]

Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.

[Ido Yofe @IdoYofe]

This

[Sherene Loi, MD @LoiSher]

➡️New from #loilab
🚩🚩Our new study shows higher baseline tumour burden predicts poorer outcomes on #immunotherapy in metastatic #breastcancer.
🚩Why this matters: maybe surveillance post early #TNBC is now ready for prime time- if ultrasensitive ctDNA can detect relapse months before imaging, we can treat at low volume, when ICI may work better. #ctDNA #LiquidBiopsy #BreastCancerAwareness

👏👏👏congrats @J_DixonDouglas 🤩
@PeterMacRes @PeterMacCC @oncoalert #bcsm

https://t.co/MpOklAgqDi

[Paolo Tarantino @PTarantinoMD]

ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. https://t.co/9DMLLo8lOn

[Ido Yofe @IdoYofe]

"We envision a future where MRD is not only detected but also targeted in a personalized manner, with the ultimate goal of eradicating it to improve survival rates"
🎯

[Anne Knisely, MD @AnneKniselyMD]

Thank you to @break_cancer for highlighting this important work!

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

New research in @CCR_AACR shows the powerful clinical utility of detecting minimal residual disease in ovarian cancer patients.
Co-first author and Gynecologic Oncology fellow at @MDAndersonNews, and co-first author on this study, @AnneKniselyMD shares her thoughts

Learn more here: https://t.co/c5nZMAkSkM
Read the full study here: https://t.co/wLeWyyHjHN

[Ido Yofe @IdoYofe]

@OdedRechavi @TyHaliburton22 Well that jinxed it

[Paolo Tarantino @PTarantinoMD]

The curves everybody’s been waiting for.

First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

[Ido Yofe @IdoYofe]

@leeat_keren Looks awesome, looking forward to trying it!

[Ido Yofe @IdoYofe]

Fantastic study!
Great work @FadiSheban @TgSanPhan @CuriousKX @FlorianIngelfi1

[IdoAmitLab @IdoAmitLab]

We are excited to share our new study @Cancer_Cell identifying Zeb2 as a master genetic switch controlling the tumor-associated macrophage (TAM) program. Led by @FadiSheban, @TgSanPhan, @CuriousKX & @FlorianIngelfi1. (1/20)
https://t.co/ZpPXUjbwRF

[Ido Yofe @IdoYofe]

@leeat_keren Nice! Congratulations everyone!
@RazBenuri
@LiorBenSha
@omerbartal
@OneViTaDay
@OferElhanani

[Merav Cohen Lab @MCohenLab]

We are beyond excited to share the first publication of our lab! We highlight the role of #neutrophils in shaping a more aggressive #TME through physical interactions with #breastcancer cells. The work was led by the talented @Sandra_Cam & @OriMoskowitz 🧵https://t.co/qpVuxfeg6q

[Ido Yofe @IdoYofe]

@RoychoudhuriLab @JieYang437 @Nature @Cambridge_Uni @CRUKCamCentre Remarkable 👏
Congratulations to all authors, inspiring work.

[Oren Barboy @orenbarboy]

Highly recommended

[Ido Yofe @IdoYofe]

The Yofe Lab at Sheba is looking for scientists:
🥼Research Associate • PhD & MSc students 🎓

Our new cancer research group is focused on studying metastasis with cutting-edge tech.

Interested? Send your CV & cover letter to:
[email protected]

[Ido Yofe @IdoYofe]

Proud to be part of @SHEBA_, a world-leading hospital.
https://t.co/yErntvv6kI

[המרכז הרפואי שיבא @SHEBA_]

גאווה ישראלית: שיבא מטפס למקום ה-8 בעולם!
המרכז הרפואי שיבא ממשיך להוביל ומטפס למקום ה-8 בדירוג בתי החולים הטובים בעולם של Newsweek – הישג בינלאומי יוצא דופן למערכת הבריאות הישראלית.
השנה האחרונה הציבה אתגר עצום, ושיבא היה בלב המענה הרפואי: